XML 244 R200.htm IDEA: XBRL DOCUMENT
v3.22.4

Other operating expenses - Other Income and Expense (Details) - EUR (€) € in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |
Other operating expenses | € 2,531 | € 1,805 | € 1,415 | [1]
Other operating income | 1,969 | 859 | 697 | [1]
Other operating income/(expenses), net related to the Regeneron Alliance | (1,231) | (1,373) | (926) |
Antibodies collaboration agreement | Regeneron Pharmaceuticals, INC |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |
Commitments received for development costs | 2,700 | 2,900 |  |
Regeneron |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |
Other operating expenses | 2,378 | 1,568 | 1,090 |
Other operating income (expense) | Regeneron |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |
Other operating income | 1,147 | 195 | 164 |
Monoclonal Antibody Alliance |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |
Other operating expenses | 2,367 | 1,429 | 1,001 |
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of monoclonal antibodies |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |
Other operating expenses | 2,325 | 1,253 | 727 |
Monoclonal Antibody Alliance | Share of profit or loss from commercialization of Zaltrap |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |
Other operating income | 434 | 127 | 75 |
Monoclonal Antibody Alliance | Commercialization related expenses |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |
Other operating expenses | 476 | 303 | 349 |
Immuno-Oncology Alliance |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |
Other operating income | 16 | 68 | 89 |
Others |  |  |  |
Disclosure Of Other Operating Income Expenses [Line Items] |  |  |  |
Other operating income and expenses | € 1,120 | € (12) | € (14) |
[1] | Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.

X
- Definition The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_MiscellaneousOtherOperatingExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of miscellaneous other operating income. [Refer: Other operating income (expense)] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 112 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_MiscellaneousOtherOperatingIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of operating income (expense) that the entity does not separately disclose in the same statement or note. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 85 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_OtherOperatingIncomeExpense
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitments Received For Development Costs + References No definition available. + Details
Name: | sny_CommitmentsReceivedForDevelopmentCosts
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disclosure of other operating income (expenses). + References No definition available. + Details
Name: | sny_DisclosureOfOtherOperatingIncomeExpensesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other operating income and expenses. + References No definition available. + Details
Name: | sny_MiscellaneousOtherOperatingIncomeExpenses
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocationAxis=sny_OtherOperatingIncomeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_AntibodiesAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocationAxis=sny_ShareOfProfitOrLossFromCommercializationOfMonoclonalAntibodiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocationAxis=sny_ShareOfProfitOrLossFromCommercializationOfZaltrapMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_IncomeStatementLocationAxis=sny_CommercializationRelatedExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_ImmunooncologyAllianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sny_OthersCounterpartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |